NSE: MEDPLUS· HealthCareCore · Aug 26Small cap
Medplus Health Services
Organised pharmacy retail
- Last close
- ₹654.00
- 29 Sept 2026 · reference
- 1D · 1M
- +0.2% · −3.3%
- price-only
- Weight
- 0.8%
- 31 Jul 2026 · Aug rank 27
- Thesis review
- 8 Sep 2026
- Why We Own, p43
Where the price sits
52-week range, house target and street targets
52w low ₹64952w high ₹954
- Reference close₹654
Range from reference closes; street targets from the PDFs on file (Research & documents). Internal target is never shown to prospects.
Investment case and valuation
Approved model, 8 Sep 2026 review
₹659
Price (2026-09-08)
40.2x / 45.7x
FY27E / FY28E P/E (Buoyant sheet)
10.4%
FY27E ROE (Buoyant sheet)
37.6x
Trailing P/E
4.0x
Price / book
9%
EPS CAGR FY26–28E
TTM PE 37.6x at a 52-week-low price; 3-yr ROE only 8.35% vs 12% in FY26; 5-yr average PE not sourced. EV/EBITDA computed on mcap + ~Rs 949 cr net debt (screener approximation, includes lease liabilities) over FY26 EBITDA. EV/EBITDA 14.6x; dividend yield 0.0%.
- Model date
- 8 Sep 2026 (prices 7–8 Sep 2026)
- Horizon
- 12 months (bank pages: Sep-2027 roll-forward)
- Audience
- Internal — the book's guardrail: do not quote a target to a client; quote the thesis and the risk
- Reviewer · version
- Investment Committee framework · v1 (book)
Current vs history
Trailing multiples, FY-end
| Ratio | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E | n.m. | n.m. | n.m. | n.m. | n.m. | 126.0x | 156.0x | 126.0x | 60.5x | 45.8x |
| Price to Book | n.m. | n.m. | n.m. | n.m. | n.m. | 8.6x | 5.3x | 5.3x | 5.3x | 5.1x |
Tijori FY-end multiples on reported earnings/book; compatible definitions across years, but not the same basis as Buoyant's forward P/E on internal EPS.
UnavailableScenario lab disabled. Needs an approved forward EPS and forward P/E for Medplus Health Services plus a reference price. Missing inputs are not substituted.